Baxter India has received approval from the Central Drugs Standard Control Organization (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, India to use Oxiris filter set for the treatment of COVID-19 patients. Oxiris blood purification filter is intended for use in critically ill COVID-19 patients in need of blood purification where excessive inflammatory Mediators are present i.e. Cytokine Storm release.
Oxiris set was earlier used with the Prismaflex Control Unit for patients in need for blood purification including Continuous Renal Replacement Therapy (CRRT) and in conditions where excessive Endotoxins and Inflammatory Mediators level exists.
“The COVID-19 cases in India have been spiralling and putting undue pressure on our healthcare system. This approval has come at a crucial time when such filter sets are much required to ease the burden on healthcare providers. We hope the availability of Oxiris will go a long way in fighting the COVID-19 cases in India. We extend our appreciation to the CDSCO for this approval”, said Ravinder Dang, VP, Commercial Excellence, APAC and General Manager, India.
During blood purification therapy, the patient’s blood passes through the Oxiris Filter Set, where it can absorb inflammatory mediators and remove fluid, electrolytes and uremic toxins, before returning the patient’s blood to the body. Making it the only filter set that does not necessitate the use of additional devices Renal Replacement Therapy (RRT) or removal of Troublesome Inflammatory Cytokines.
Oxiris is currently in use across countries in Europe and Asia and has been used for more than 10 years to treat thousands of patients. Oxiris has been validated for use with Baxter’s leading PrisMax and Prismaflex Systems.